tiprankstipranks
Advertisement
Advertisement

TSHA Stock Latest News

Unusually active option classes on open April 16th
The FlyUnusually active option classes on open April 16th
18d ago
PEP
BULL
Buy Rating on Taysha Gene Therapies Driven by Strong Leadership, Strategic Positioning, and Attractive Risk‑Reward Upside
PremiumRatings
Buy Rating on Taysha Gene Therapies Driven by Strong Leadership, Strategic Positioning, and Attractive Risk‑Reward Upside
19d ago
TSHA
Advancing Gene Therapy Programs and Strengthened Valuation Support Taysha Buy Rating and $17 Target
PremiumRatings
Advancing Gene Therapy Programs and Strengthened Valuation Support Taysha Buy Rating and $17 Target
28d ago
TSHA
Taysha Gene Therapies price target raised to $17 from $14 at Canaccord
PremiumThe Fly
Taysha Gene Therapies price target raised to $17 from $14 at Canaccord
28d ago
TSHA
Taysha Gene Therapies Signals Momentum in Earnings Call
PremiumCompany Announcements
Taysha Gene Therapies Signals Momentum in Earnings Call
2M ago
TSHA
Taysha Gene Therapies reports 2025 EPS (34c), consensus (34c)
PremiumThe FlyTaysha Gene Therapies reports 2025 EPS (34c), consensus (34c)
2M ago
TSHA
Taysha Gene Therapies management to meet with Cantor
Premium
The Fly
Taysha Gene Therapies management to meet with Cantor
2M ago
TSHA
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
Premium
The Fly
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
2M ago
TSHA
TSHA Earnings this Week: How Will it Perform?
PremiumPre-Earnings
TSHA Earnings this Week: How Will it Perform?
2M ago
TSHA
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
PremiumThe Fly
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
3M ago
TSHA
Aehr, Fastenal, Regions, Abeona, Taysha: Insider Firestorm
PremiumWeekend Updates
Aehr, Fastenal, Regions, Abeona, Taysha: Insider Firestorm
3M ago
RF
ABEO
Regulatory Clarity and Broad Rett Syndrome Opportunity Drive Taysha Gene Therapies Buy Rating and $10 Target
PremiumRatings
Regulatory Clarity and Broad Rett Syndrome Opportunity Drive Taysha Gene Therapies Buy Rating and $10 Target
4M ago
TSHA
Taysha Gene Therapies announces progress across TSHA-102
PremiumThe FlyTaysha Gene Therapies announces progress across TSHA-102
4M ago
TSHA
Taysha Gene Therapies price target raised to $11 from $8 at Wells Fargo
Premium
The Fly
Taysha Gene Therapies price target raised to $11 from $8 at Wells Fargo
4M ago
TSHA
Taysha Gene Therapies rated Buy versus Early-Stage at Goldman Sachs
Premium
The Fly
Taysha Gene Therapies rated Buy versus Early-Stage at Goldman Sachs
5M ago
TSHA
Taysha price target raised to $19 from $13 at Cantor Fitzgerald
PremiumThe Fly
Taysha price target raised to $19 from $13 at Cantor Fitzgerald
5M ago
TSHA
Citizens JMP healthcare analysts hold an analyst/industry conference
PremiumThe Fly
Citizens JMP healthcare analysts hold an analyst/industry conference
6M ago
BNTC
CRSP
FDA appoints Richard Pazdur as Director of CDER
PremiumThe Fly
FDA appoints Richard Pazdur as Director of CDER
6M ago
AZN
BMY
Taysha Gene Therapies price target raised to $8 from $6 at Citizens JMP
PremiumThe Fly
Taysha Gene Therapies price target raised to $8 from $6 at Citizens JMP
6M ago
TSHA
Taysha Gene Therapies Advances TSHA-102 Program
PremiumCompany AnnouncementsTaysha Gene Therapies Advances TSHA-102 Program
6M ago
TSHA
Taysha Gene Therapies’ Earnings Call Highlights Progress and Challenges
Premium
Company Announcements
Taysha Gene Therapies’ Earnings Call Highlights Progress and Challenges
6M ago
TSHA
Taysha Gene Therapies: Advancing REVEAL Study and Mitigating Regulatory Risks Earns Buy Rating
Premium
Ratings
Taysha Gene Therapies: Advancing REVEAL Study and Mitigating Regulatory Risks Earns Buy Rating
6M ago
TSHA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >